Paper Details

  1. Home
  2. Paper Details

Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy.

Author: JefferyDouglas R

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This article discusses the changing therapeutic landscape for multiple sclerosis (MS) due to the development of new pharmacologic agents and advances in testing for exposure to the JC virus. Fingolimod, the first oral agent approved for MS, is now widely used. Natalizumab is now being used as a first-line agent in patients negative for JC virus antibodies. Teriflunomide and BG-12 are expected to be approved soon, providing additional treatment options.
Paper Details　
Original Abstract of the Article :
The development of new pharmacologic agents for the treatment of multiple sclerosis (MS) and advances in testing for exposure to the JC virus have led to changes in the treatment of MS. In addition several new agents are in late stage development for MS and their entry onto the market will provide a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539264/

データ提供：米国国立医学図書館（NLM）

New Treatments for Multiple Sclerosis: A Landscape of Options

Multiple sclerosis (MS), a chronic inflammatory disease that affects the central nervous system, presents a significant challenge for researchers and clinicians. This article provides an overview of recent advances in MS treatment, including the development of new medications and the increasing availability of JC virus antibody testing.

The article highlights the emergence of several new oral medications for MS, including fingolimod, teriflunomide, and BG-12. The authors discuss the efficacy and safety profiles of these drugs, emphasizing their potential to expand treatment options for patients with MS. The article also explores the changing role of natalizumab, a monoclonal antibody previously reserved for specific patient populations, due to the availability of JC virus antibody testing.

The Future of MS Treatment: A Horizon of Hope

This article offers a glimpse into the evolving landscape of MS treatment. The emergence of new medications and advancements in diagnostic testing provide a more comprehensive approach to managing this complex disease, offering hope for improved outcomes for patients.

Navigating the Journey of MS Treatment

This article is like a camel caravan navigating the complex and ever-changing desert of MS treatment. It provides valuable insights into the latest advancements, offering a roadmap for patients and healthcare providers to find the most effective and safe treatment options.

Dr. Camel's Conclusion

This article is like a camel caravan traversing the vast and challenging desert of multiple sclerosis research. The emergence of new treatment options and diagnostic advancements offer a glimmer of hope for patients, suggesting that the horizon of MS treatment is brightening.

Date :
  1. Date Completed 2013-01-24
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

23342246

DOI: Digital Object Identifier

PMC3539264

Related Literature

Article Analysis
・Effects of natalizumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.